Centocor's Simponi Becomes First TNF Blocker To Escape REMS Duties

FDA's release of Centocor from a Risk Evaluation and Mitigation Strategy for Simponi could signal a reprieve from the REMS regulatory burden for other tumor necrosis factor inhibitors as well.